Nkgen Biotech Inc (NKGN) - News Archive

In a notable development in the field of biotechnology, NKGen Biotech and HekaBio have announced a strategic partnership aimed at advancing the development and commercialization of an innovative autologous NK cell thera...

Abstract: NKGen Biotech is at the forefront of developing innovative cellular therapies, including Troculeucel, which shows promise in treating post-stroke and Alzheimer’s disease (AD) patients. Recent advancements incl...

Emerging Therapeutic Frontier: NKGen Biotech s Innovative Step Forward in Frontotemporal Dementia Treatment Amid Financial Challenges NKGen Biotech Inc. a company immersed in the cutting-edge landscape of biotechnology,...

Recent developments from NKGen Biotech highlight significant strides in the treatment of two major health challenges: moderate Alzheimer s disease (AD) and advanced solid tumors. The company s innovative approach, lever...

NKGen Biotech, a forward-thinking clinical-stage biotechnology company, is making significant strides in the field of natural killer (NK) cell therapies, positioning itself as a key player in the evolving landscape of c...

NKGen Biotech Presents Updated Phase 1 Data on SNK02 Allogeneic NK Cell Therapy for Solid Tumors at the 6th Annual Allogeneic Cell Therapies Summit 2024SANTA ANA, Calif., June 12, 2024 - NKGen Biotech, a leading clinica...

NKGen Biotech, a clinical-stage biotechnology company, is set to present updated Phase 1 data on its SNK02 allogeneic NK cell therapy in solid tumors at the 6th Annual Allogeneic Cell Therapies Summit. The event will ta...

In recent years, immunotherapy has revolutionized cancer treatment by harnessing the power of the immune system to target and eliminate cancer cells. While immune checkpoint inhibitors have proven successful, recent bre...

Emerging Cell Therapy Shows Promise with No Adverse Drug-Related Events In recent developments heralding a potential breakthrough in Alzheimer s disease treatment, NKGen Biotech s SNK01, an autologous enhanced natural k...

Revolutionary NKGen Biotech s SNK01: Potent NK Cell Therapy Unveiled at Prestigious CGCS SummitSANTA ANA, Calif., May 16, 2024 - NKGen Biotech, Inc. (Nasdaq: NKGN) has set the stage for a groundbreaking presentation at...

In an exciting development for the field of neurodegenerative diseases, NKGen Biotech has recently announced the FDA clearance of its Investigational New Drug (IND) Application for SNK01 NK Cell Therapy in Parkinson s D...

Rejuvenating Hope: NKGen Biotech Presents Breakthrough SNK01 NK Cell Therapy for Neurodegenerative Diseases at Prestigious SummitSANTA ANA, Calif., April 18, 2024 - NKGen Biotech, Inc. (Nasdaq: NKGN) (NKGen or the Compa...

IntroductionNKGen Biotech Inc, a leading biotechnology company focused on neurodegenerative diseases, has announced significant progress in its clinical programs for Alzheimer s and Parkinson s diseases. Alongside this...

NKGen Biotech Makes Progress in Alzheimer s Disease Treatment: Promising Phase 1 Clinical Trial Data PresentedNKGen Biotech, a leading biopharmaceutical company, presented additional data from their Phase 1 clinical tri...

NKGen Biotech, Inc. Announces Promising Results in its Groundbreaking Alzheimer s Treatment TrialIn a groundbreaking development, NKGen Biotech, a leading biotechnology company, has recently initiated the first patient...

In a significant development, NKGen Biotech has recently announced the clearance of the clinical trial application by Health Canada for their groundbreaking SNK01 NK cell therapy, aimed at treating patients with moderat...